Toby N. Trahair

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 379 citations

Interleukin 2, Autoimmune Disease, Anti-gd2 Antibody Ch14.18/cho +7

Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer

Marie Wong, Chelsea Mayoh, Loretta M. S. Lau et al. · Nature Medicine · 2020 · 372 citations

Functional Genomics, High-risk Pediatric Cancer, Medicine +9

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 334 citations · Full text

Oncology, Medicine, Versus Carboplatin +8

β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma

Eddy Pasquier, Janine Street, Charlotte Pouchy et al. · British Journal of Cancer · 2013 · 158 citations · Full text

Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma

Laura D. Gamble, Stefania Purgato, Jayne Murray et al. · Science Translational Medicine · 2019 · 155 citations